In support of this, Belmontes et al. found that the most important factor for bispecific T-cell engager efficacy in multiple solid-tumour in vivo models was pretreatment T-cell density in the tumour, with CD8+ T-cells being the most important mediator of bispecific T-cell engager activity [14]. The gene discussed is CD8A; the disease is neoplasm.